Ifeanyi Oguagha
Internal Medicine · Arverne, NYNPI 1093031056
Payments from drug & device makers
Across 339 payments — averaging $22.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Lilly USA, LLC$875
- AbbVie$854
- AstraZeneca$719
- Neurocrine Biosciences, Inc.$519
- GSK$513
- plus $3K from 25 others
What the payments were for
- Food & beverage$7,48499%
- Education$901%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 52 | $1,209 |
| Lilly USA, LLC | 42 | $875 |
| AbbVie | 27 | $854 |
| AstraZeneca | 41 | $719 |
| Neurocrine Biosciences, Inc. | 22 | $519 |
| GSK | 24 | $513 |
| Merck | 18 | $345 |
| Viiv Healthcare Company | 15 | $332 |
| Teva Pharmaceuticals USA, Inc. | 12 | $271 |
| Pfizer | 12 | $268 |
| Bayer | 7 | $253 |
| Exact Sciences | 9 | $186 |
| Dexcom, Inc. | 3 | $167 |
| Gilead | 8 | $163 |
| Renalytix AI, Inc. | 6 | $124 |
| Johnson & Johnson(2 entities) | 7 | $118 |
| Amarin Pharma, Inc. | 6 | $114 |
| Boehringer Ingelheim | 5 | $81 |
| Phadia US Inc. | 3 | $68 |
| Amgen | 4 | $66 |
| Shield Therapeutics Inc | 3 | $61 |
| Global Blood Therapeutics, Inc. | 2 | $47 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $42 |
| Philips North America LLC | 2 | $41 |
| Vertex | 1 | $26 |
| Novartis | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Indivior Inc. | 1 | $20 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Lundbeck LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,574 in reported general payments places this provider in the 90th percentile of 9,771 internal medicine providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RybelsusSemaglutide | 74 | $123,109 |
| LofenaDiclofenac Potassium | 11 | $86,786 |
| Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate | 30 | $63,895 |
| OzempicSemaglutide | 43 | $55,612 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 54 | $49,972 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 44 | $47,428 |
| LinzessLinaclotide | 58 | $43,198 |
| EntrestoSacubitril/Valsartan | 30 | $30,905 |
| DescovyEmtricitabine/Tenofov Alafenam | 14 | $30,713 |
| Diclofenac Epolamine | 26 | $28,778 |
| TivicayDolutegravir Sodium | 12 | $27,234 |
| Doxepin Hcl | 33 | $26,999 |
| Diclofenac Potassium | 21 | $26,901 |
| KerendiaFinerenone | 20 | $25,289 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 16 | $25,125 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $1,209 | $178,722117 claims |
| AstraZenecaBreztri Aerosphere, Farxiga | $719 | $61,90666 claims |
| GSKTrelegy Ellipta | $513 | $47,42844 claims |
| AbbVieLinzess | $854 | $43,19858 claims |
| MerckJanumet Xr, Janumet | $345 | $36,87335 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $875 | $35,75529 claims |
| NovartisEntresto | $21 | $30,90530 claims |
| GileadDescovy | $163 | $30,71314 claims |
| Viiv Healthcare CompanyTivicay | $332 | $27,23412 claims |
| BayerKerendia | $253 | $25,28920 claims |
| Boehringer IngelheimJardiance | $81 | $21,55121 claims |
| PfizerEliquis | $268 | $20,01620 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Arverne
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
- Patrick ReaganRochester$9.4M
- Sally LauNew York$8.4M
- Angela BrancheRochester$7.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.